[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-muscle-invasive-bladder-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-muscle-invasive-bladder-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,87,115,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629875","phase-3-efficacy-and-safety-of-intravesical-tara-002-compared-with-investigators-choice-of-intravesical-chemotherapy-in-participants-with-bcg-nave-high-grade-non-muscle-invasive-bladder-cancer-100629875",false,"NCT07480356","Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer","ADVANCED-3","Inclusion Criteria:\n\n* Male or female participants 18 years of age or older at the time of signing informed consent\n* Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry\n* Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta\u002FT1) with active disease\n* Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis, or participants who received ≤2 doses of BCG within the 24 months prior to the most recent CIS diagnosis\n\nExclusion Criteria:\n\n* Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory\n* Central confirmed variant histology\n* Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment\n* Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)\n* Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history\n\nFor more information on eligibility criteria, please contact the Sponsor.","ALL","18 Years",{"count":20,"type":21},284,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.\n\nThe main questions it aims to answer are:\n\n* Can the study drug help participants with this type of cancer?\n* Is the study drug safe?\n* What are the side effects of the study drug?\n\nResearchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.",[27,28,29],"Bladder (Urothelial, Transitional Cell) Cancer","Non-Muscle Invasive Bladder Carcinoma","Non-muscle Invasive Bladder Cancer With Carcinoma in Situ",[31,32,33,34],"BCG-naive","Non-muscle invasive bladder Cancer","bladder cancer","carcinoma in situ","RECRUITING","2026-08-20",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":39},"2026-05-29",{"date":43,"type":21},"2032-11",{"name":45,"class":46},"Protara Therapeutics","INDUSTRY",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100648779","phase-1-a-phase-1-dose-escalation-study-of-ugn-501-administered-intravesically-in-adult-participants-with-recurrent-nmibc-100648779","NCT07725796","A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC","A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","Inclusion Criteria:\n\n1. Participant must be 18 years of age or older at the time of signing informed consent.\n2. Has confirmed recurrent non-muscle invasive bladder cancer (NMIBC) with high-grade Ta and\u002For T1 disease and\u002For carcinoma in situ (CIS), or recurrent low-grade Ta and\u002For T1 disease.\n3. Participants with high-grade Ta and\u002For T1 disease and\u002For CIS must meet one of the following criteria:\n\n   * Has BCG-unresponsive disease, defined as:\n   * persistent or recurrent CIS alone or with recurrent Ta\u002FT1 disease within 12 months of completion of adequate BCG therapy; or\n   * recurrent high-grade Ta\u002FT1 disease within 6 months of completion of adequate BCG therapy; or\n   * high-grade T1 disease at the first evaluation following a BCG induction course.\n\n   Adequate BCG therapy is defined as at least 5 of 6 doses of an initial induction course plus either at least 2 of 3 doses of maintenance therapy or at least 2 of 6 doses of a second induction course. Participants with BCG-unresponsive disease also must be unwilling or unfit to undergo radical cystectomy.\n   * Is BCG-exposed, defined as high-grade persistent or recurrent NMIBC within 24 months of the last dose of BCG but not meeting the definition of BCG-unresponsive disease, and received at least 5 of 6 doses of an initial induction course of BCG.\n   * Is BCG intolerant, defined as the inability to tolerate at least 1 full induction course of BCG.\n   * Has a high-grade Ta tumor ≤3 cm and failed at least 1 previous course of therapy, such as TURBT plus an adjuvant induction course of intravesical chemotherapy.\n4. Participants with low-grade disease must meet one of the following criteria:\n\n   * Ta tumors recurring within 1 year.\n   * Ta solitary tumor \\>3 cm.\n   * Ta multifocal tumors.\n   * T1 tumors.\n5. All visible papillary tumors must be resected and obvious areas of CIS fulgurated during Screening or within 6 weeks before Screening. Participants with T1 disease should have a re-staging TURBT during Screening or within 6 weeks before Screening. Enhanced cystoscopy, such as blue light cystoscopy or other locally accepted modalities, is permitted, but the same modality must be used for all subsequent disease assessments.\n6. Has Eastern Cooperative Oncology Group performance status score ≤2.\n7. Has no concomitant upper tract urothelial carcinoma (UTUC) or urothelial carcinoma within the prostatic stroma. Freedom from upper tract disease, if clinically indicated, must be demonstrated by no evidence of upper tract tumor by either IV pyelogram, retrograde pyelogram, CT urogram with or without contrast, MRI urogram with or without contrast, or ureteroscopy with ureteral washing for cytology, performed within 6 months of enrollment. Participants with urothelial carcinoma involving the prostatic urethra, where carcinoma is confined to the ducts and\u002For epithelium, may be included after a restaging TURBT is performed to rule out more extensive disease involving the prostatic stroma.\n8. Participants with prostate cancer may be eligible if, after surgery or radiation, they do not meet criteria for biochemical recurrence, or if they are on active surveillance at very low, low, or favorable risk for progression, defined as Gleason Grade Group 1 or 2, Gleason score ≤7, prostate-specific antigen \\\u003C20 ng\u002FdL, and cT1-cT2b, at the discretion of the investigator.\n9. Has adequate organ and bone marrow function within 14 days of treatment initiation, as determined by routine laboratory tests:\n\n   * Leukocytes ≥3000\u002FμL.\n   * Absolute neutrophil count ≥1500\u002FμL.\n   * Platelets ≥100,000\u002FμL.\n   * Hemoglobin ≥9.0 g\u002FdL.\n   * Total bilirubin ≤1.5 × upper limit of normal (ULN).\n   * Aspartate aminotransferase (AST) ≤2.5 × UL\n   * Alanine aminotrasferase (ALT) ≤2.5 × ULN.\n   * Alkaline phosphatase ≤2.5 × ULN.\n   * Estimated creatinine clearance ≥30 mL\u002Fmin using the Cockcroft-Gault equation.\n10. Has a life expectancy \\>12 months.\n11. Participants and participant partners must agree to follow contraception and barrier method requirements consistent with local regulations and the protocol during the study intervention period and for at least 12 weeks after the last study intervention instillation.\n12. Has signed informed consent and is willing and able to comply with the requirements and restrictions listed in the informed consent form and protocol.\n\nExclusion Criteria:\n\n1. Current or previous evidence of muscle invasive, locally advanced nonresectable, or metastatic urothelial carcinoma, including T2, T3, T4, and\u002For stage IV disease.\n2. Current systemic therapy for bladder cancer.\n3. Prior treatment with any human adenovirus-based therapy, such as nadofaragene firadenovec-vncg or cretostimogene grenadenorepvec.\n4. Intravesical therapy within 4 weeks before starting study intervention, including but not limited to BCG, chemotherapy, and nogapendekin alfa inbakicept.\n5. Participation in a study of an investigational agent with receipt of study therapy, or receipt of an investigational device, within 4 weeks before the first dose of study intervention.\n6. Receipt of immune modulator therapy within 5 half-lives of starting study intervention, including but not limited to pembrolizumab, BCG, and nogapendekin alfa inbakicept.\n7. Receipt of a vaccine or anti-viral agent within 2 weeks before starting study intervention.\n8. Active infection requiring systemic therapy, including urinary tract infection. Participants may enter the study once the infection is satisfactorily treated.\n9. Immunocompromised state, including but not limited to HIV infection or any condition that required systemic immunosuppressive treatment in the past 2 years, such as active systemic autoimmune disease or solid organ or stem cell transplant. Short courses (≤14 days) of steroids for medical reasons without anticancer intent, such as atopic dermatitis, psoriasis, infection, or allergic reaction, are permitted if the last dose was at least 4 weeks before the first dose of study intervention.\n10. Any medical, psychological, familial, sociological, or geographical condition that, in the opinion of the investigator, would preclude participation in the study.\n11. History of malignancy of another organ system within the past 5 years, except previously treated UTUC, basal cell carcinoma or squamous cell carcinoma of the skin, and\u002For prostate cancer meeting protocol-specified criteria.\n12. Cannot tolerate intravesical dosing or intravesical surgical manipulation.\n13. Known allergy or hypersensitivity to any of the study interventions or any study intervention excipients.",{"count":56,"type":21},30,[58],"PHASE1","This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).",[27,61,62,63,64,65,28,66],"NMIBC","Urothelial Carcinoma Bladder","Urothelial Carcinoma in Situ","Urothelial Carcinoma Recurrent","Urothelial Carcinoma of the Urinary Bladder","Non-muscle Invasive Bladder Cancer (NMIBC)",[68,69,70,71,72,73,74,75],"CIS","Ta bladder cancer","T1 bladder cancer","BCG-unresponsive NMIBC","BCG-exposed NMIBC","BCG-intolerant NMIBC","Intravesical therapy","Oncolytic Virus","NOT_YET_RECRUITING","2026-07-21",{"date":79,"type":39},"2026-07-24",{"date":81,"type":21},"2026-09-30",{"date":83,"type":21},"2029-08-02",{"name":85,"class":46},"UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.",11,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100572445","phase-2-a-cruciferous-vegetable-eating-program-for-the-reduction-of-cancer-recurrence-and-progression-in-patients-with-non-muscle-invasive-bladder-cancer-100572445","NCT06733363","A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer","A Scalable Cruciferous Vegetable Intervention to Reduce Bladder Cancer Recurrence and Progression","Inclusion Criteria:\n\n* English speaking\n\n  * Diagnosed with stage Tis, Ta, or T1 bladder cancer\n  * Age 18 years old or older (no upper limit)\n  * Resides in New York State\n  * Cancer not reported by a lab, nursing home, or death certificate\u002Fautopsy only\n  * Did not receive a partial or radical cystectomy\n  * Does not have other cancer diagnosis within 12 month of bladder cancer diagnosis except for cancers deemed low risk and unlikely to impact study participation (e.g., basal cell carcinoma, nor under active treatment for any other cancers\n\nExclusion Criteria:\n\n* Participants who had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n\n  * Adults unable to consent\n  * Adults unable to complete study measures in English\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * Unwilling or unable to follow protocol requirements\n  * The following special populations ae excluded from this study:\n\n    * Cognitively impaired adults\u002Fadults with impaired decision-making capacity\n    * Individuals who are not yet adults (infants, children, teenagers)\n    * Pregnant women\n    * Prisoners",{"count":95,"type":21},344,[97],"PHASE2","This phase II trial is being done to develop and test a healthy eating program to reduce cancer recurrence (cancer that has come back after a period of improvement) and\u002For progression (cancer that is growing, spreading, or getting worse) in patients with non-muscle invasive bladder cancer (NMIBC). Researchers want to better understand how incorporating more cruciferous vegetables in the diet may reduce the risk of cancer recurrence or progression in men and women who were diagnosed with early-stage bladder cancer and compare whether extending the program can further improve bladder cancer outcomes. POW-R Health is a behavioral dietary intervention designed to modestly increase cruciferous vegetable (cruciferae) intake in patients. Cruciferous vegetables, such as cabbage, kale and broccoli, arugula, contain phytochemicals known as isothiocyanates (ITCs). Dietary ITCs exert potent anticancer activities against bladder cancer and can be rapidly metabolized, delivered to the bladder, and concentrated in the urine. Participating in the healthy eating program may reduce bladder cancer recurrence or progression in NMIBC survivors.",[28,100,101,102,103],"Recurrent Bladder Carcinoma","Recurrent Non-Muscle Invasive Bladder Carcinoma","Stage 0a Bladder Cancer AJCC v8","Stage 1 Bladder Cancer AJCC v8","2026-05-07",{"date":106,"type":39},"2026-05-08",{"date":108,"type":39},"2026-01-13",{"date":110,"type":21},"2029-02-28",{"name":112,"class":113},"Roswell Park Cancer Institute","OTHER",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":114},"100570203","phase-1-in-home-intravesical-chemotherapy-for-the-treatment-of-bladder-cancer-invite-trial-100570203","NCT06704191","In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","MC240502: Cancer CARE (Connected Access and Remote Expertise) Beyond Walls In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib\u002FII, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes","Inclusion Criteria:\n\n* PHASE IB ONLY: Female or male patients with histologically confirmed non-muscle invasive bladder cancer (stage Ta, Tis, or T1) who are currently receiving induction therapy with one of the following eligible intravesical treatment regimens\n\n  * Gemcitabine\n  * Sequential gemcitabine\u002Fdocetaxel\n  * Bacillus Calmette-Guerin\n  * Mitomycin C\n* PHASE II ONLY: Female or male patients with histologically confirmed non-muscle invasive bladder cancer (stage Ta, Tis or T1) who are receiving maintenance therapy with an eligible regimen\n* PHASE IB ONLY: Able to be successfully catheterized and able to tolerate first dost of intravesical therapy in the outpatient clinic\n* Residing within the area serviced by supplier network\n* Residence either has Wi-Fi or cellular data network connection for virtual telehealth visits\n* Age ≥ 18 years at time of registration\n* Signed informed consent form by patient\n* Willing and able to comply with the study protocol in the investigator's judgment\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willingness to follow birth control requirements for females and males of reproductive potential\n\nExclusion Criteria:\n\n* Receiving any other investigational or standard of care agent which would be considered as a treatment for non-muscle invasive bladder cancer and is not part of the eligible treatment regimens\n* Actively receiving any other treatment for cancer (except hormone therapy for breast or prostate cancer, or treatment for non-invasive skin cancer)\n* Requiring 24\u002F7 assistance with activities of daily living (ADLs)\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Myocardial infarction ≤ 6 months\n  * Wound healing disorder\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Anticipation of the need for major surgery during the course of study treatment\n* Known allergy or previous intolerance to drug regimens\n* Pregnancy or breastfeeding\n* Hypersensitivity or allergy to polysorbate 80 or paclitaxel",{"count":123,"type":21},40,[58,97],"This phase Ib\u002FII trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasive bladder cancer is usually given directly into the bladder through a catheter (intravesical). This process requires numerous visits and can be disruptive to the lives of patients and caregivers. Bringing cancer care to the patients with in-home intravesical therapy may help reduce the disruption to daily lives. In-home intravesical chemotherapy may be safe and tolerable and may also be preferable to in-clinic administration in patients with non-muscle invasive bladder cancer.",[28,102,127,128],"Stage I Bladder Cancer AJCC v8","Stage 0is Bladder Cancer AJCC v8","2026-03-24",{"date":131,"type":39},"2026-03-30",{"date":133,"type":39},"2025-04-21",{"date":135,"type":21},"2026-12-31",{"name":137,"class":113},"Mayo Clinic",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":114},"100629426","phase-4-studying-the-relationship-of-patient-positioning-and-intravesical-bacillus-calmette-guerin-dwell-time-to-improve-the-treatment-of-non-muscle-invasive-bladder-cancer-100629426","NCT07474519","Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer","An Assessment of Patient Position and Intravesical BCG Dwell Time","Inclusion Criteria:\n\n* Patient with intermediate or high risk NMIBC opting for intravesical induction BCG\n* Has not initiated induction therapy\n* Able to remain in supine position for two hours. (Head may be raised on up to two pillows)\n* Able to remain in a sitting position for two hours\n* Willingness to utilize a wearable fitness tracker for at least five days during the study\n* Able to perform a remote video or telephone encounter\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Receipt of intravesical BCG within the past 1 year\n* Known inability to retain BCG\n* History of urinary incontinence with a score of 3 or more on the Overactive Bladder Survey (OAB) urgency, urgency incontinence, or incontinence questions\n* Refusal to wear a fitness tracker during a 24-hour baseline, during treatment, and\u002For for 2 hours post treatment",{"count":123,"type":21},[147],"PHASE4","This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time) to improve the treatment of non-muscle invasive bladder cancer. For the past 40 years, intravesical BCG has been used for the treatment of non-muscle invasive bladder cancer. An important factor for BCG treatment is the dwell time, which is the period of time a patient can hold the BCG medication in the bladder after it has been given. Normally, patients are instructed during intravesical BCG treatment to avoid emptying the bladder for 2 hours after the BCG is given. However, this may be difficult for some patients who may have limited bladder capacity, restricted movement, or severe urinary symptoms. There have been studies outlining the relationship with increased dwell time and how well the treatment works, but studies on the potential impact of patient positioning or activity on the patient's ability to retain the drug are limited. Researchers hope by studying whether there is a relationship between patient positioning during intravesical BCG treatment and dwell time, they may be able to improve how BCG treatment for non-muscle invasive bladder cancer is given, especially for patients with limited bladder capacity, restricted movement, or severe urinary symptoms.",[28],"2026-03-11",{"date":152,"type":39},"2026-03-16",{"date":154,"type":39},"2026-02-26",{"date":156,"type":21},"2027-12-31",{"name":158,"class":113},"Ohio State University Comprehensive Cancer Center"]